» Articles » PMID: 23274672

Azole Affinity of Sterol 14α-demethylase (CYP51) Enzymes from Candida Albicans and Homo Sapiens

Overview
Specialty Pharmacology
Date 2013 Jan 1
PMID 23274672
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Candida albicans CYP51 (CaCYP51) (Erg11), full-length Homo sapiens CYP51 (HsCYP51), and truncated Δ60HsCYP51 were expressed in Escherichia coli and purified to homogeneity. CaCYP51 and both HsCYP51 enzymes bound lanosterol (K(s), 14 to 18 μM) and catalyzed the 14α-demethylation of lanosterol using Homo sapiens cytochrome P450 reductase and NADPH as redox partners. Both HsCYP51 enzymes bound clotrimazole, itraconazole, and ketoconazole tightly (dissociation constants [K(d)s], 42 to 131 nM) but bound fluconazole (K(d), ~30,500 nM) and voriconazole (K(d), ~2,300 nM) weakly, whereas CaCYP51 bound all five medical azole drugs tightly (K(d)s, 10 to 56 nM). Selectivity for CaCYP51 over HsCYP51 ranged from 2-fold (clotrimazole) to 540-fold (fluconazole) among the medical azoles. In contrast, selectivity for CaCYP51 over Δ60HsCYP51 with agricultural azoles ranged from 3-fold (tebuconazole) to 9-fold (propiconazole). Prothioconazole bound extremely weakly to CaCYP51 and Δ60HsCYP51, producing atypical type I UV-visible difference spectra (K(d)s, 6,100 and 910 nM, respectively), indicating that binding was not accomplished through direct coordination with the heme ferric ion. Prothioconazole-desthio (the intracellular derivative of prothioconazole) bound tightly to both CaCYP51 and Δ60HsCYP51 (K(d), ~40 nM). These differences in binding affinities were reflected in the observed 50% inhibitory concentration (IC(50)) values, which were 9- to 2,000-fold higher for Δ60HsCYP51 than for CaCYP51, with the exception of tebuconazole, which strongly inhibited both CYP51 enzymes. In contrast, prothioconazole weakly inhibited CaCYP51 (IC(50), ~150 μM) and did not significantly inhibit Δ60HsCYP51.

Citing Articles

Access to Substituted Tricyclic Heteroarenes by an Oxidative Cyclization Reaction and Their Antifungal Performance.

Nakiwala R, Dasgupta N, Wilson R, Lutter E, Bolliger J Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006062 PMC: 11860112. DOI: 10.3390/ph18020249.


The fungicide propiconazole induces hepatic steatosis and activates PXR in a mouse model of diet-induced obesity.

Attema B, Kummu O, Krutakova M, Pavek P, Hakkola J, Hooiveld G Arch Toxicol. 2024; 99(3):1203-1221.

PMID: 39718591 DOI: 10.1007/s00204-024-03942-9.


Design, Synthesis, Investigation, and Biological Activity Assessments of (4-Substituted-Phenyl)--(3-morpholinopropyl)-3-phenylthiazol-2(3)-imine Derivatives as Antifungal Agents.

Haji Ali S, Osmaniye D, Saglik B, Levent S, Ozkay Y, Kaplancikli Z ACS Omega. 2024; 9(38):39326-39343.

PMID: 39346840 PMC: 11425616. DOI: 10.1021/acsomega.3c07879.


Advancements in the nanodelivery of azole-based fungicides to control oil palm pathogenic fungi.

Asmawi A, Adam F, Mohd Azman N, Rahman M Heliyon. 2024; 10(18):e37132.

PMID: 39309766 PMC: 11416272. DOI: 10.1016/j.heliyon.2024.e37132.


Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.

Abdelmonem B, Abdelaal N, Anwer E, Rashwan A, Hussein M, Ahmed Y Biomedicines. 2024; 12(7).

PMID: 39062040 PMC: 11275228. DOI: 10.3390/biomedicines12071467.


References
1.
Pfaller M, Diekema D . Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1):133-63. PMC: 1797637. DOI: 10.1128/CMR.00029-06. View

2.
Hasselberg L, Grosvik B, Goksoyr A, Celander M . Interactions between xenoestrogens and ketoconazole on hepatic CYP1A and CYP3A, in juvenile Atlantic cod (Gadus morhua). Comp Hepatol. 2005; 4(1):2. PMC: 549046. DOI: 10.1186/1476-5926-4-2. View

3.
Konkle M, Hargrove T, Kleshchenko Y, von Kries J, Ridenour W, Uddin M . Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J Med Chem. 2009; 52(9):2846-53. PMC: 2744100. DOI: 10.1021/jm801643b. View

4.
Ekins S, Mankowski D, Hoover D, Lawton M, Treadway J, Harwood Jr H . Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2006; 35(3):493-500. DOI: 10.1124/dmd.106.013888. View

5.
Sims C, Ostrosky-Zeichner L, Rex J . Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res. 2005; 36(6):660-71. DOI: 10.1016/j.arcmed.2005.05.015. View